SG11202003664TA - Nucleic acid-binding photoprobes and uses thereof - Google Patents
Nucleic acid-binding photoprobes and uses thereofInfo
- Publication number
- SG11202003664TA SG11202003664TA SG11202003664TA SG11202003664TA SG11202003664TA SG 11202003664T A SG11202003664T A SG 11202003664TA SG 11202003664T A SG11202003664T A SG 11202003664TA SG 11202003664T A SG11202003664T A SG 11202003664TA SG 11202003664T A SG11202003664T A SG 11202003664TA
- Authority
- SG
- Singapore
- Prior art keywords
- photoprobes
- binding
- nucleic acid
- nucleic
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/16—Compounds containing azido groups with azido groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C247/18—Compounds containing azido groups with azido groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/101—Crosslinking agents, e.g. psoralen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/205—Aptamer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593175P | 2017-11-30 | 2017-11-30 | |
PCT/US2018/063490 WO2019109046A1 (en) | 2017-11-30 | 2018-11-30 | Nucleic acid-binding photoprobes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003664TA true SG11202003664TA (en) | 2020-05-28 |
Family
ID=66664240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003664TA SG11202003664TA (en) | 2017-11-30 | 2018-11-30 | Nucleic acid-binding photoprobes and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (2) | US11807623B2 (de) |
EP (1) | EP3717009A4 (de) |
JP (2) | JP2021505132A (de) |
CN (1) | CN111386127A (de) |
AU (1) | AU2018374389A1 (de) |
CA (1) | CA3078540A1 (de) |
IL (2) | IL297543A (de) |
MX (1) | MX2020003695A (de) |
RU (1) | RU2020112854A (de) |
SG (1) | SG11202003664TA (de) |
WO (1) | WO2019109046A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
US20220251545A1 (en) * | 2019-06-27 | 2022-08-11 | The Scripps Research Institute | Fragment-based screening to identify small molecules that selectively bind rna |
US20230176063A1 (en) * | 2020-03-20 | 2023-06-08 | Academia Sinica | Photoreactive and cleavable probes for tagging biomolecules |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB288885A (en) | 1927-08-17 | 1928-04-19 | John Robert English | A new or improved three-way or four-way junction box or connector for electric conductors |
LU55777A1 (de) | 1967-04-14 | 1968-06-16 | ||
FR2540122B1 (fr) * | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
WO2001007657A1 (en) | 1999-07-27 | 2001-02-01 | Phylos, Inc. | Peptide acceptor ligation methods |
IL93682A (en) | 1989-03-16 | 1996-06-18 | Yeda Res & Dev | Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them |
US5514786A (en) | 1990-01-11 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Compositions for inhibiting RNA activity |
AU732820B2 (en) | 1995-06-02 | 2001-05-03 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
JPH08502966A (ja) | 1992-10-23 | 1996-04-02 | ユニバーシティー・オブ・マサチューセッツ・メディカル・センター | Rna/リガンド結合の低分子抑制 |
US5534408A (en) | 1993-09-24 | 1996-07-09 | University Of Massachusetts Medical Center | 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
US5585069A (en) | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
US6229002B1 (en) | 1995-06-07 | 2001-05-08 | Nexstar Pharmaceuticlas, Inc. | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
WO2001094626A1 (en) | 1999-04-30 | 2001-12-13 | Cyclops Genome Sciences Limited | Polynucleotides |
US7303867B2 (en) | 1999-12-16 | 2007-12-04 | Katayanagi Institute | Method for detecting target nucleotide sequences |
DE10012823A1 (de) * | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
WO2002028808A1 (en) | 2000-10-06 | 2002-04-11 | Kansas State University Research Foundation | Triptycene analogs |
AU2002234165A1 (en) | 2000-11-03 | 2002-05-27 | Tularik, Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
CZ305402B6 (cs) | 2001-02-24 | 2015-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthinové deriváty, jejich výroba a použití v kombinační terapii |
CA2516091C (en) | 2002-03-11 | 2016-03-08 | Simon Fraser University | Dna and rna conformational switches as sensitive electronic sensors of analytes |
US20030198966A1 (en) | 2002-04-19 | 2003-10-23 | Stojanovic Milan N. | Displacement assay for detection of small molecules |
US7285285B2 (en) | 2002-05-13 | 2007-10-23 | L'oreal | Photoactivatable diazirine-active agent compounds, compositions comprising them and uses thereof |
CA2492273C (en) | 2002-07-12 | 2013-02-05 | Paratek Pharmaceuticals, Inc. | 3, 10, and 12a substituted tetracycline compounds |
US7964722B2 (en) | 2002-08-31 | 2011-06-21 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Light-driven rotary molecular motors |
US20040121337A1 (en) | 2002-12-19 | 2004-06-24 | Nomadics, Inc. | Luminescent polymers and methods of use thereof |
WO2005073338A2 (en) | 2003-12-04 | 2005-08-11 | Massachusetts Institute Of Technology | Fluorescent, semi-conductive polymers, and devices comprising them |
US7759127B2 (en) | 2003-12-05 | 2010-07-20 | Massachusetts Institute Of Technology | Organic materials able to detect analytes |
US7687146B1 (en) | 2004-02-11 | 2010-03-30 | Zyvex Labs, Llc | Simple tool for positional diamond mechanosynthesis, and its method of manufacture |
CA2500938A1 (en) | 2004-03-24 | 2005-09-24 | Rohm And Haas Company | Memory devices based on electric field programmable films |
WO2005106035A2 (en) | 2004-04-09 | 2005-11-10 | Cornell Research Foundation, Inc. | Modular design and construction of nucleic acid molecules, aptamer-derived nucleic acid constructs, rna scaffolds, their expression, and methods of use |
US7723498B2 (en) | 2004-06-04 | 2010-05-25 | University Of Connecticut | Directed evolution of recombinant monooxygenase nucleic acids and related polypeptides and methods of use |
US7745614B2 (en) | 2004-09-03 | 2010-06-29 | The Board Of Trustees Of The Leland Stanford Junior University | Universal linker compositions for the release or transfer of chemical agents from a polynucleotide |
US8617819B2 (en) | 2004-09-17 | 2013-12-31 | Massachusetts Institute Of Technology | Polymers for analyte detection |
US8466132B2 (en) | 2004-10-25 | 2013-06-18 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
CN101056980B (zh) | 2004-11-08 | 2012-05-23 | 威泊根私人有限公司 | 结构型核酸指导的化学合成 |
JP5420174B2 (ja) | 2004-12-23 | 2014-02-19 | ジーイー・ヘルスケア・バイオサイエンス・コーポレイション | ライゲーションによるrna増幅法 |
EP2319940A1 (de) | 2005-01-04 | 2011-05-11 | Hitachi Chemical Company, Ltd. | RCA mit Primererzeugung |
WO2006089083A2 (en) | 2005-02-18 | 2006-08-24 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Low-loss filter and frequency multiplexer |
US20070009201A1 (en) | 2005-07-08 | 2007-01-11 | Rohm And Haas Electronic Materials Llc | Electric field programmable films and memory devices based thereon |
CA2633636A1 (en) | 2005-11-15 | 2007-05-24 | The General Hospital Corporation | Photoactivatable antimicrobial agents |
CN101438288A (zh) | 2006-03-15 | 2009-05-20 | Csir公司 | 谷氨酰胺合成酶的磷酰基转移酶活性的调节 |
US7928211B2 (en) | 2006-05-03 | 2011-04-19 | Vipergen Pharmaceuticals Aps | Method for preparing compounds by nucleic acid directed synthesis |
WO2007145940A2 (en) | 2006-06-05 | 2007-12-21 | The University Of North Carolina At Chapel Hill | High-throughput rna structure analysis |
WO2008066873A2 (en) | 2006-11-29 | 2008-06-05 | The Research Foundation Of State University Of New York | Methods for identifying ligands that target nucleic acid molecules and nucleic acid structural motifs |
US8715635B2 (en) | 2007-02-06 | 2014-05-06 | Technion Research & Development Foundation Limited | Frictionless molecular rotary motors |
US20100170796A1 (en) | 2007-02-08 | 2010-07-08 | Massachusetts Institute Of Technology | In Vitro Microfluidic Model of Microcirculatory Diseases, and Methods of Use Thereof |
EP2591795B1 (de) * | 2007-02-23 | 2018-02-28 | The Research Foundation Of State University Of New York | RNA-Target-Verbindungen und Verfahren zu ihrer Herstellung und Verwendung |
US20110008304A1 (en) | 2007-07-09 | 2011-01-13 | Kansas State University Research Foundation | Use of cells to facilitate targeted delivery of nanoparticle therapies |
US9029524B2 (en) | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
WO2009077173A2 (en) | 2007-12-19 | 2009-06-25 | Philochem Ag | Dna-encoded chemical libraries |
JP2009263435A (ja) | 2008-04-23 | 2009-11-12 | Fujifilm Corp | 光硬化性コーティング組成物、オーバープリント及びその製造方法 |
WO2009157938A1 (en) | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
US8313424B2 (en) | 2008-10-02 | 2012-11-20 | Pericles Gabrielidis | Sex toy |
EP2432794B1 (de) | 2009-05-22 | 2017-08-30 | The Research Foundation of State University of New York | Rna-umschalter mit trans-wirkung |
US9732337B2 (en) | 2009-06-16 | 2017-08-15 | The United Stated of America, as represented by the Secretary, Department of Health & Human Services | RNA nanoparticles and nanotubes |
AU2009352490B2 (en) | 2009-09-14 | 2013-06-20 | Suven Life Sciences Limited | 1, 2-dihydro-2-oxoquinoline compounds as 5-HT 4 receptor ligands |
US9677125B2 (en) | 2009-10-21 | 2017-06-13 | General Electric Company | Detection of plurality of targets in biological samples |
US9156938B2 (en) | 2010-08-19 | 2015-10-13 | Massachusetts Institute Of Technology | Compositions, methods, and systems comprising fluorous-soluble polymers |
US8783281B2 (en) | 2010-09-13 | 2014-07-22 | GM Global Technology Operations LLC | Fuel tank temperature and pressure management via selective extraction of liquid fuel and fuel vapor |
JP6193761B2 (ja) | 2010-09-27 | 2017-09-06 | ビペルゲン | 富化ライブラリーを作製する方法 |
FR2968302B1 (fr) | 2010-12-06 | 2012-11-30 | Biomerieux Sa | Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits |
US20130338178A1 (en) | 2011-02-02 | 2013-12-19 | The Trustees Of Princeton University | Sirtuin modulators as inhibitors of cytomegalovirus |
US9757497B2 (en) * | 2011-05-20 | 2017-09-12 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
WO2013025930A1 (en) | 2011-08-16 | 2013-02-21 | Research Foundation of State University of New York at Albany | Aptamer modulators of estrogen receptors |
JP6200500B2 (ja) | 2012-07-10 | 2017-09-20 | ベースクリック ゲーエムベーハー | アナンダミド−修飾核酸分子 |
JP2015527322A (ja) | 2012-07-10 | 2015-09-17 | ジョージア ステイト ユニバーシティ リサーチ ファンデーション, インコーポレイテッド | アントラキノン類似体ならびにその作製方法および使用方法 |
EP2688093B1 (de) | 2012-07-19 | 2018-07-18 | Technische Universität Ilmenau | Verfahren und Vorrichtung zur Selbstmontage mittels eines Fluids von Komponenten auf einem Substrat |
FR2994184B1 (fr) | 2012-08-02 | 2017-12-08 | Biomerieux Sa | Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride aza-isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits |
TWI668217B (zh) * | 2012-08-24 | 2019-08-11 | 廣東東陽光藥業有限公司 | 二氫嘧啶類化合物及其在藥物中的應用 |
WO2014036395A1 (en) | 2012-08-30 | 2014-03-06 | The Scripps Research Institute | SMALL MOLECULES TARGETING REPEAT r(CGG) SEQUENCES |
KR20150093685A (ko) * | 2012-11-09 | 2015-08-18 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 | Hbv 어셈블리 이펙터의 대체 용도 |
US20140145673A1 (en) | 2012-11-29 | 2014-05-29 | Joseph Heilbrun | System for Simultaneously Charging Multiple Portable Electronic Devices |
TWI499552B (zh) | 2012-12-07 | 2015-09-11 | Univ Nat Cheng Kung | 液滴產生方法及裝置 |
US10597650B2 (en) | 2012-12-21 | 2020-03-24 | New England Biolabs, Inc. | Ligase activity |
US20140212869A1 (en) | 2013-01-25 | 2014-07-31 | Agilent Technologies, Inc. | Nucleic Acid Proximity Assay Involving the Formation of a Three-way junction |
EP2948968B1 (de) | 2013-01-28 | 2018-03-28 | Massachusetts Institute of Technology | Elektromechanische vorrichtung |
WO2014145620A2 (en) | 2013-03-15 | 2014-09-18 | The Broad Institute, Inc. | Novel hybridization probes and uses thereof |
CA2907490A1 (en) | 2013-03-20 | 2014-09-25 | Indiana University Research And Technology Corporation | Fluorescent-hap: a diagnostic stain for hbv cores in cells |
GB201306097D0 (en) | 2013-04-04 | 2013-05-22 | Isis Innovation | Sensor |
WO2014175018A1 (ja) | 2013-04-22 | 2014-10-30 | 株式会社日立ハイテクノロジーズ | 自動分析装置 |
US9586944B2 (en) | 2013-07-15 | 2017-03-07 | The Scripps Research Institute | Specific targeting of RNA expanded repeat sequences |
US20150020944A1 (en) | 2013-07-17 | 2015-01-22 | The Goodyear Tire & Rubber Company | Pneumatic tire having a single carcass ply reinforced with polyester cords |
KR20160037943A (ko) | 2013-08-02 | 2016-04-06 | 길레아드 메로스 | 나선형 환상 도로 풀 인터체인지 시스템 |
US10157261B2 (en) | 2013-08-09 | 2018-12-18 | The Scripps Research Institute | Transcriptome-wide design of selective, bioactive small molecules targeting RNA |
WO2015021990A1 (en) | 2013-08-16 | 2015-02-19 | University Of Copenhagen | Rna probing method and reagents |
ES2712090T3 (es) | 2013-08-29 | 2019-05-09 | Scripps Research Inst | Moléculas pequeñas ensambladas modularmente para el tratamiento de la distrofia miotónica tipo 1 |
CA2923427A1 (en) | 2013-09-06 | 2015-03-12 | Massachusetts Institute Of Technology | Devices and methods including a preconcentrator material for detection of analytes |
WO2015042184A2 (en) | 2013-09-17 | 2015-03-26 | Hocuslocus, Llc | Methods of using structurally interacting rna |
ES2708779T3 (es) | 2013-09-30 | 2019-04-11 | Mitsubishi Heavy Ind Thermal Systems Ltd | Sistema de bomba de calor, y calentador de agua de bomba de calor |
CN103479384B (zh) | 2013-09-30 | 2015-11-18 | 无锡市凯顺医疗器械制造有限公司 | 一种导音管、导音管制备方法及模具 |
WO2015054247A1 (en) | 2013-10-07 | 2015-04-16 | The University Of North Carolina At Chapel Hill | Detection of chemical modifications in nucleic acids |
WO2015063952A1 (ja) | 2013-11-01 | 2015-05-07 | 富士機械製造株式会社 | フィーダ |
CA2839771A1 (en) | 2013-11-29 | 2015-05-29 | The Governors Of The University Of Alberta | Binding-induced formation of dna three-way junctions |
WO2015094958A1 (en) | 2013-12-18 | 2015-06-25 | Albert Einstein College Of Medicine Of Yeshiva University | Method of rapid isolation of aptamer beacons |
GB201402646D0 (en) | 2014-02-14 | 2014-04-02 | Eth Z Rich | Polymers |
ES2686508T3 (es) | 2014-05-29 | 2018-10-18 | Siemens Aktiengesellschaft | Emisor fosforescente binuclear de metales del grupo principal |
WO2016011348A1 (en) | 2014-07-18 | 2016-01-21 | The Scripps Research Institute | Toxic rna inhibitors self-assembled in situ |
US11021502B2 (en) | 2014-08-04 | 2021-06-01 | The Trustees Of The University Of Pennsylvania | Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA) |
NZ730296A (en) | 2014-08-20 | 2023-09-29 | Alnylam Pharmaceuticals Inc | Modified double-stranded rna agents |
WO2016069922A1 (en) | 2014-10-29 | 2016-05-06 | Biotium, Inc. | Nucleic acid modifying agents and uses thereof |
US10731202B2 (en) * | 2014-11-24 | 2020-08-04 | Battelle Memorial Institute | Chromatin activity precipitation method and system |
EP3352872A4 (de) | 2015-09-24 | 2019-07-10 | The Trustees of the University of Pennsylvania | Triptycenderivate zur stabilisierung einer nukleinsäureverbindung |
WO2017064156A1 (en) | 2015-10-16 | 2017-04-20 | F. Hoffmann-La Roche Ag | Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
EP3411080A4 (de) | 2016-02-01 | 2019-08-14 | Arrakis Therapeutics, Inc. | Verbindungen und methoden zur behandlung von rna-vermittelten erkrankungen |
WO2017136403A1 (en) * | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
RU2018145144A (ru) | 2016-07-01 | 2020-08-03 | Арракис Терапьютикс, Инк. | Соединения и способы для модуляции функции рнк |
-
2018
- 2018-11-30 EP EP18883560.7A patent/EP3717009A4/de active Pending
- 2018-11-30 CN CN201880076222.8A patent/CN111386127A/zh active Pending
- 2018-11-30 US US16/207,062 patent/US11807623B2/en active Active
- 2018-11-30 SG SG11202003664TA patent/SG11202003664TA/en unknown
- 2018-11-30 AU AU2018374389A patent/AU2018374389A1/en active Pending
- 2018-11-30 CA CA3078540A patent/CA3078540A1/en active Pending
- 2018-11-30 MX MX2020003695A patent/MX2020003695A/es unknown
- 2018-11-30 IL IL297543A patent/IL297543A/en unknown
- 2018-11-30 WO PCT/US2018/063490 patent/WO2019109046A1/en unknown
- 2018-11-30 RU RU2020112854A patent/RU2020112854A/ru unknown
- 2018-11-30 JP JP2020529485A patent/JP2021505132A/ja active Pending
-
2020
- 2020-05-25 IL IL274900A patent/IL274900A/en unknown
-
2023
- 2023-01-17 US US18/155,528 patent/US20230312520A1/en active Pending
- 2023-12-07 JP JP2023206834A patent/JP2024015264A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021505132A (ja) | 2021-02-18 |
RU2020112854A (ru) | 2021-12-30 |
WO2019109046A9 (en) | 2019-07-04 |
US20230312520A1 (en) | 2023-10-05 |
CA3078540A1 (en) | 2019-06-06 |
CN111386127A (zh) | 2020-07-07 |
JP2024015264A (ja) | 2024-02-01 |
WO2019109046A1 (en) | 2019-06-06 |
IL297543A (en) | 2022-12-01 |
EP3717009A4 (de) | 2021-12-01 |
EP3717009A1 (de) | 2020-10-07 |
AU2018374389A1 (en) | 2020-05-07 |
US11807623B2 (en) | 2023-11-07 |
US20190270723A1 (en) | 2019-09-05 |
MX2020003695A (es) | 2020-08-03 |
IL274900A (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201900317B (en) | Somatostatin modulators and uses thereof | |
HK1255034A1 (zh) | 生長抑素調節劑及其用途 | |
IL261140B (en) | Antibodies against tnf-alpha and functional fragments thereof | |
ZA202108602B (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
IL287825A (en) | Structures of sirp-alpha variant and their uses | |
HK1255074A1 (zh) | 生長抑素調節劑及其用途 | |
IL274900A (en) | Nucleic acid-binding photoprobes and their uses | |
IL261261A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
IL261098A (en) | Antibodies against tnf-alpha and functional fragments thereof | |
IL254241A0 (en) | Etv2 and its uses | |
IL261793A (en) | Anti-tnfalpha antibodies and their functional parts | |
IL275211A (en) | Fast and flexible segment chains - division | |
IL273671A (en) | Cornoline variants and their use | |
IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
GB201711352D0 (en) | Nucleic acids and uses thereof | |
GB201622225D0 (en) | Modified host cells and uses thereof | |
GB201617925D0 (en) | Proteins and uses |